NEW YORK CITY (dpa-AFX) - ViiV Healthcare Ltd and Shionogi & Co., Ltd. Sunday announced an agreement revising their integrase inhibitor relationship, for ViiV to acquire the exclusive global rights to the Shionogi-ViiV Healthcare LLC joint venture assets. Shionogi will receive ongoing royalty and dividend stream as well as 10 percent equity in ViiV Healthcare.
ViiV Healthcare is a global specialist HIV company, established in November 2009 by GlaxoSmithKline (GSK, GSK.L) and Pfizer Inc. (PFE).
The assets include the investigational medicine dolutegravir and some early stage integrase inhibitor compounds.
Isao Teshirogi, CEO of Shionogi, said, 'The new deal perfectly aligns with the strategic goals and capabilities of both companies. Shionogi are able to secure a continued revenue stream from the integrase inhibitor portfolio as well as a stake in ViiV Healthcare itself...'
Copyright RTT News/dpa-AFX